- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02018536
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.
16 de junho de 2014 atualizado por: Janssen R&D Ireland
A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK2336805 (Part 1), Followed by an Open-label, Randomized, 4-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Co-administration of TMC435 and GSK2336805 at Steady-state (Part 2), in Healthy Japanese Subjects
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (what the body does to a medication) of GSK2336805 alone and with the co-administration of TMC435 in healthy Japanese participants.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
- Medicamento: GSK2336805 30 mg
- Medicamento: GSK2336805 60 mg
- Medicamento: GSK2336805 120 mg
- Medicamento: TMC435 150 mg (Treatment A)
- Medicamento: GSK2336805 60 mg (Treatment B and part of Treatment C and D)
- Medicamento: TMC435 100 mg (part of Treatment C)
- Medicamento: TMC435 150 mg (part of treatment D)
Descrição detalhada
This study will consists of 2 parts (Part 1 and 2) which will be sequentially conducted in 2 separate panels of 24 healthy adult Japanese participants each, at a single center.
Part 1 is a double-blind (neither physician nor participant knows the treatment that the participant receives), placebo-controlled (placebo is compared with the study medication to test whether the study medication has a real effect in clinical study), randomized (study medication is assigned by chance), single ascending dose study to investigate the safety, tolerability, and pharmacokinetics of GSK2336805 in participants.
It will consist of a screening phase, a treatment phase, and a follow-up phase.
The maximum study duration for each participant will be approximately 5 weeks (including screening and follow-up phase).
24 participants will be equally divided in 3 cohorts with 8 participants in each cohort.
In each cohort, participants will be randomly assigned to receive either a single oral dose of GSK2336805 (6 participants) or placebo (2 participants).
Part 2 is an open-label (all people know the identity of the intervention), randomized, 4-way crossover study (method used to switch patients from one treatment arm to another in a clinical study) to investigate the potential pharmacokinetic drug-drug interactions between TMC435 and GSK2336805 at steady-state, and to evaluate the short-term safety and tolerability when TMC435 and GSK2336805 are co-administered in participants.
It will consist of a screening phase, a treatment phase (4 treatment sessions [Treatment A, B, C, and D]), and a follow-up phase.
The maximum study duration for each participant will be approximately 12 weeks (including screening and follow-up phase).
During 4 treatment sessions, each of the 24 participants will receive Treatment A, B, C and D consecutively in different sequences with a washout period of at least 7 days between consecutive treatment sessions in each individual participant.
Safety will be evaluated by assessing adverse events, clinical laboratory tests, electrocardiogram, vital signs, physical examination, alcohol breath tests, and specific toxicities.
Tipo de estudo
Intervencional
Inscrição (Real)
48
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
California
-
Cypress, California, Estados Unidos
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
20 anos a 55 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Healthy Japanese participants on the basis of medical history, physical examination, vital signs, triplicate 12-lead electrocardiogram, and clinical laboratory testing performed at screening
- Must have signed an Informed Consent Form (ICF) indicating they understand the purpose of and procedures required for the study
- Must be willing to adhere to the prohibitions and restrictions specified in the protocol
- Women must be of non-childbearing potential (postmenopausal for at least 2 years or surgically sterile)
- Women, except for postmenopausal women, should have a negative serum b-human chorionic gonadotropin (hCG) pregnancy test at screening
Exclusion Criteria:
- History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use within the past one year
- Participants with hepatitis A, B, or C infection or human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection at study screening
- Female participants who are breastfeeding at screening
- History of liver or renal impairment; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplastic, or metabolic disturbances
- Participants with known allergies, hypersensitivity, or intolerance to GSK2336805, TMC435 or excipients of the drug products used
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Part 1, Cohort A
8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
|
A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
|
Experimental: Part 1, Cohort B
8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
|
A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
|
Experimental: Part 1, Cohort C
8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
|
A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
|
Experimental: Part 2, Sequence 1
6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
|
1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
|
Experimental: Part 2, Sequence 2
6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
|
1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
|
Experimental: Part 2, Sequence 3
6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
|
1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
|
Experimental: Part 2, Sequence 4
6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
|
1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Part 1: Maximum observed plasma concentration of GSK2336805
Prazo: Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Part 1: Area under the plasma concentration-time curve of GSK2336805
Prazo: Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Part 1: The actual sampling time to reach the maximum observed plasma concentration of GSK2336805
Prazo: Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16 hours), Day 2 (24 and 36 hour), Day 3, and time point of early withdrawal
|
Part 2: Maximum observed plasma concentration of TMC435
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Part 2: Area under the plasma concentration-time curve of TMC435
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Part 2: The actual sampling time to reach the maximum observed plasma concentration of TMC435
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Part 2: Maximum observed plasma concentration of GSK2336805
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Part 2: Area under the plasma concentration-time curve of GSK2336805
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Part 2: The actual sampling time to reach the maximum observed plasma concentration of GSK2336805
Prazo: Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Predose, postdose on Day 1 (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 2, Day 5, Day 6, Day 7 (predose and postdose (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours), Day 8, Day 9, Day 10, and time point of early withdrawal
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Part 1 and 2: Number of participants with adverse events
Prazo: Up to 12-14 weeks
|
Number of participants with adverse events as a measure of safety and tolerability after administration of TMC435 alone, GSK2336805 alone, and after TMC435 administration in combination with GSK2336805
|
Up to 12-14 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de outubro de 2013
Conclusão Primária (Real)
1 de março de 2014
Conclusão do estudo (Real)
1 de março de 2014
Datas de inscrição no estudo
Enviado pela primeira vez
17 de dezembro de 2013
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de dezembro de 2013
Primeira postagem (Estimativa)
23 de dezembro de 2013
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
17 de junho de 2014
Última atualização enviada que atendeu aos critérios de controle de qualidade
16 de junho de 2014
Última verificação
1 de junho de 2014
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CR102928
- TMC435HPC1012 (Outro identificador: Janssen R&D Ireland)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em GSK2336805 30 mg
-
Fondazione OncotechAinda não está recrutando
-
Otsuka Pharmaceutical Development & Commercialization...Bill and Melinda Gates FoundationConcluídoUm teste de fase 1/2 de múltiplas doses orais de OPC-167832 para tuberculose pulmonar não complicadaTB pulmonarÁfrica do Sul
-
Regeneron PharmaceuticalsConcluídoInfecções por Vírus Sincicial RespiratórioEstados Unidos, Austrália, Bulgária, Canadá, Chile, Dinamarca, Finlândia, Alemanha, Hungria, Holanda, Nova Zelândia, Panamá, Porto Rico, África do Sul, Espanha, Suécia, Peru, Ucrânia, Reino Unido
-
GlaxoSmithKlinePPDConcluídoHepatite C CrônicaPorto Rico, Estados Unidos, Bulgária, Alemanha, Bélgica, França
-
Vigonvita Life SciencesConcluído
-
Cerevel Therapeutics, LLCRecrutamento
-
Galderma R&DConcluídoPrurigo nodularEstados Unidos, Alemanha, Áustria, Canadá, Dinamarca, Hungria, Itália, Polônia, Suécia, Reino Unido
-
PfizerConcluídoInsuficiência Hepática | Participantes SaudáveisEstados Unidos
-
AllerganConcluídoEnxaqueca CrônicaEstados Unidos, Austrália, Canadá, China, Tcheca, Dinamarca, França, Alemanha, Itália, Japão, Republica da Coréia, Polônia, Federação Russa, Espanha, Suécia, Taiwan, Reino Unido
-
Merck Sharp & Dohme LLCRescindidoCarcinoma pulmonar de células não pequenas | Anemia | Câncer de bexiga | Câncer de Cabeça e Pescoço | Câncer de colo uterino | Carcinoma Pulmonar de Pequenas Células